JP2007527714A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007527714A5 JP2007527714A5 JP2006553313A JP2006553313A JP2007527714A5 JP 2007527714 A5 JP2007527714 A5 JP 2007527714A5 JP 2006553313 A JP2006553313 A JP 2006553313A JP 2006553313 A JP2006553313 A JP 2006553313A JP 2007527714 A5 JP2007527714 A5 JP 2007527714A5
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- composition
- seq
- disease
- complement protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091023037 Aptamer Proteins 0.000 claims 83
- 239000000203 mixture Substances 0.000 claims 72
- 201000010099 disease Diseases 0.000 claims 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 28
- 102000000989 Complement System Proteins Human genes 0.000 claims 25
- 108010028773 Complement C5 Proteins 0.000 claims 21
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 230000001404 mediated effect Effects 0.000 claims 13
- 239000002773 nucleotide Substances 0.000 claims 13
- 230000001154 acute effect Effects 0.000 claims 12
- 208000037891 myocardial injury Diseases 0.000 claims 12
- 238000001727 in vivo Methods 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 238000001356 surgical procedure Methods 0.000 claims 10
- 239000003937 drug carrier Substances 0.000 claims 9
- 206010052779 Transplant rejections Diseases 0.000 claims 8
- 239000003085 diluting agent Substances 0.000 claims 8
- 230000036470 plasma concentration Effects 0.000 claims 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 6
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 5
- 208000035473 Communicable disease Diseases 0.000 claims 4
- 108010069112 Complement System Proteins Proteins 0.000 claims 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 208000025966 Neurological disease Diseases 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 206010063837 Reperfusion injury Diseases 0.000 claims 4
- 208000025747 Rheumatic disease Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 230000007815 allergy Effects 0.000 claims 4
- 238000002399 angioplasty Methods 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 208000037976 chronic inflammation Diseases 0.000 claims 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 4
- 208000023589 ischemic disease Diseases 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 206010028417 myasthenia gravis Diseases 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 208000037803 restenosis Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 230000035939 shock Effects 0.000 claims 4
- 208000017520 skin disease Diseases 0.000 claims 4
- 101100440311 Homo sapiens C5 gene Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000010790 dilution Methods 0.000 claims 3
- 239000012895 dilution Substances 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 230000021615 conjugation Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 150000002634 lipophilic molecules Chemical class 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000007026 protein scission Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54454204P | 2004-02-12 | 2004-02-12 | |
| US60/544,542 | 2004-02-12 | ||
| US54774704P | 2004-02-25 | 2004-02-25 | |
| US60/547,747 | 2004-02-25 | ||
| US58168504P | 2004-06-21 | 2004-06-21 | |
| US60/581,685 | 2004-06-21 | ||
| US60804804P | 2004-09-07 | 2004-09-07 | |
| US60/608,048 | 2004-09-07 | ||
| PCT/US2005/004606 WO2005079363A2 (en) | 2004-02-12 | 2005-02-14 | Aptamer therapeutics useful in the treatment of complement-related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007527714A JP2007527714A (ja) | 2007-10-04 |
| JP2007527714A5 true JP2007527714A5 (https=) | 2008-04-03 |
| JP5242918B2 JP5242918B2 (ja) | 2013-07-24 |
Family
ID=34891329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006553313A Expired - Lifetime JP5242918B2 (ja) | 2004-02-12 | 2005-02-14 | 補体関連障害の治療に有用なアプタマー治療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7538211B2 (https=) |
| EP (5) | EP3736335A1 (https=) |
| JP (1) | JP5242918B2 (https=) |
| CY (3) | CY1114443T1 (https=) |
| DK (3) | DK1727567T3 (https=) |
| ES (4) | ES2531075T3 (https=) |
| HU (2) | HUE038239T2 (https=) |
| LT (2) | LT3385384T (https=) |
| PL (2) | PL2860251T3 (https=) |
| PT (3) | PT3385384T (https=) |
| SI (2) | SI2860251T1 (https=) |
| TR (1) | TR201808488T4 (https=) |
| WO (1) | WO2005079363A2 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395888B1 (en) * | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| DK2070939T3 (da) * | 2001-05-25 | 2014-06-23 | Univ Duke | Modulatorer af farmakologiske midler |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| PL1615945T3 (pl) | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| US20090075342A1 (en) * | 2005-04-26 | 2009-03-19 | Sharon Cload | Metabolic profile directed aptamer medicinal chemistry |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| MX2008002395A (es) * | 2005-08-19 | 2008-03-18 | Neose Technologies Inc | Factor vii y factor viia glicopegilados. |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| AU2006325030B2 (en) * | 2005-12-16 | 2012-07-26 | Cellectis | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
| NZ571791A (en) * | 2006-03-08 | 2012-03-30 | Archemix Llc | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
| EP2049144B8 (en) | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylation of peptides via o-linked glycosylation sequences |
| EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES |
| HUE026001T2 (en) | 2007-02-05 | 2016-04-28 | Apellis Pharmaceuticals Inc | Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system |
| AU2008228247A1 (en) * | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
| HRP20130382T1 (hr) | 2007-04-03 | 2013-05-31 | Biogenerix Ag | Postupci lijeäśenja pomoä†u glikopegiliranog g-csf |
| CA2690611C (en) | 2007-06-12 | 2015-12-08 | Novo Nordisk A/S | Improved process for the production of nucleotide sugars |
| EP2562256A3 (en) * | 2007-09-24 | 2013-06-19 | Noxxon Pharma AG | C5a binding nucleic acids |
| NZ586099A (en) * | 2007-11-19 | 2012-05-25 | Carefusion 2200 Inc | Patient interface assembly comprising a jet pump including a venturi assembly defining an entrainment region, a throat region and an expansion region |
| WO2009073821A2 (en) * | 2007-12-04 | 2009-06-11 | Archemix Corp. | Biopolymer-nucleic acid conjugation |
| PL2257311T3 (pl) | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Koniugaty cząsteczek czynnika VIII |
| WO2010108657A2 (en) * | 2009-03-23 | 2010-09-30 | Noxxon Pharma Ag | C5a binding nucleic acids and the use thereof |
| US8236570B2 (en) | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
| US8841429B2 (en) | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
| RU2410432C1 (ru) * | 2009-11-23 | 2011-01-27 | Государственное учреждение Научно-исследовательский институт физико-химической биологии имени А.Н. Белозерского Московского государственного университета имени М.В. Ломоносова | Модифицированные днк аптамеры, ингибирующие активность тромбина |
| EP2468295A1 (en) * | 2010-12-21 | 2012-06-27 | Affiris AG | Vaccines based on peptides of the complement protein C5a |
| EP3524258B1 (en) | 2011-06-22 | 2025-10-01 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| KR102034203B1 (ko) * | 2012-01-10 | 2019-10-18 | 아프타리온 바이오테크 아게 | 새로운 C5a 결합 핵산 |
| EP2666785A1 (en) * | 2012-05-23 | 2013-11-27 | Affiris AG | Complement component C5a-based vaccine |
| MX366404B (es) | 2012-11-15 | 2019-07-08 | Apellis Pharmaceuticals Inc | Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados. |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| EP2978451B1 (en) | 2013-03-29 | 2019-11-27 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| US11903994B2 (en) | 2015-10-07 | 2024-02-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| TWI826364B (zh) | 2017-04-03 | 2023-12-21 | 德商因夫萊亞斯有限公司 | 活性抑制劑於發炎性疾病之治療 |
| IL269844B2 (en) | 2017-04-07 | 2025-01-01 | Apellis Pharmaceuticals Inc | Dosage regimens and related compositions and methods |
| US10450345B2 (en) | 2017-06-09 | 2019-10-22 | General Electric Company | Method of isolation of polypeptide-aptamer-polymer conjugates |
| TWI786132B (zh) | 2017-06-23 | 2022-12-11 | 德商因夫萊亞斯有限公司 | 活性抑制劑於發炎性疾病之治療 |
| WO2019118938A1 (en) | 2017-12-15 | 2019-06-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| RU2703799C1 (ru) * | 2018-05-31 | 2019-10-22 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Днк-аптамеры, взаимодействующие с протромбином |
| US20220356234A1 (en) | 2019-10-02 | 2022-11-10 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
| PH12022552556A1 (en) | 2020-03-27 | 2024-04-22 | Inflarx Gmbh | Inhibitors of c5a for the treatment of corona virus infection |
| TW202208427A (zh) | 2020-05-06 | 2022-03-01 | 德商因夫萊亞斯有限公司 | 人源化抗ｃ５ａ抗體 |
| JP2023525581A (ja) | 2020-05-15 | 2023-06-16 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体の活性化を検出するための細胞外小胞の使用方法、並びに補体性疾患の処置を評価及び／又は監視するためのその使用 |
| WO2024238422A1 (en) | 2023-05-12 | 2024-11-21 | Alexion Pharmaceuticals, Inc. | Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles |
| WO2024238421A1 (en) | 2023-05-12 | 2024-11-21 | Alexion Pharmaceuticals, Inc. | Use of biomarkers for the identification and treatment of complement-mediated disorders |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
| WO2025176843A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof |
| WO2026027707A1 (en) | 2024-08-02 | 2026-02-05 | Sandoz Ag | Pre-filled syringe containing avacincaptad formulation |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4959309A (en) | 1983-07-14 | 1990-09-25 | Molecular Diagnostics, Inc. | Fast photochemical method of labelling nucleic acids for detection purposes in hybridization assays |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DE229046T1 (de) | 1985-03-30 | 1987-12-17 | Marc Genf/Geneve Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| GB2181661B (en) | 1985-10-22 | 1989-09-20 | Nat Res Dev | Improvements in or relating to apparatus for removing settled sludge from liquid |
| US4935363A (en) | 1987-03-30 | 1990-06-19 | Board Of Regents, The University Of Texas System | Sterol regulatory elements |
| WO1989006694A1 (en) | 1988-01-15 | 1989-07-27 | Trustees Of The University Of Pennsylvania | Process for selection of proteinaceous substances which mimic growth-inducing molecules |
| US5070010A (en) | 1989-10-30 | 1991-12-03 | Hoffman-La Roche Inc. | Method for determining anti-viral transactivating activity |
| JPH05501060A (ja) | 1990-03-21 | 1993-03-04 | アイシス・ファーマシューティカルス・インコーポレーテッド | Ｒｎａ模倣による遺伝子発現活性変調のための試薬および方法 |
| US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
| US5789157A (en) | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
| US6395888B1 (en) * | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US5668264A (en) | 1990-06-11 | 1997-09-16 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5861254A (en) | 1997-01-31 | 1999-01-19 | Nexstar Pharmaceuticals, Inc. | Flow cell SELEX |
| US6140490A (en) * | 1996-02-01 | 2000-10-31 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5654151A (en) | 1990-06-11 | 1997-08-05 | Nexstar Pharmaceuticals, Inc. | High affinity HIV Nucleocapsid nucleic acid ligands |
| US5674685A (en) | 1990-06-11 | 1997-10-07 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
| US5705337A (en) | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
| US5459015A (en) | 1990-06-11 | 1995-10-17 | Nexstar Pharmaceuticals, Inc. | High-affinity RNA ligands of basic fibroblast growth factor |
| US5683867A (en) | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5635615A (en) | 1990-06-11 | 1997-06-03 | Nexstar Pharmaceuticals, Inc. | High affinity HIV nucleocapsid nucleic acid ligands |
| US5763173A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
| US5648214A (en) | 1990-06-11 | 1997-07-15 | University Research Corporation | High-affinity oligonucleotide ligands to the tachykinin substance P |
| US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5707796A (en) | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| JPH06503715A (ja) | 1990-09-21 | 1994-04-28 | フレッド ハッチンソン キャンサー リサーチ センター | タンパク質配列特異的オリゴヌクレオチド配列 |
| ES2061416T3 (es) | 1990-10-12 | 1997-03-01 | Max Planck Gesellschaft | Ribozimas modificadas. |
| JPH06508022A (ja) | 1991-02-21 | 1994-09-14 | ギリアド サイエンシズ，インコーポレイテッド | 生体分子に特異的なアプタマーおよび生産方法 |
| WO1992014842A1 (en) | 1991-02-21 | 1992-09-03 | Gilead Sciences, Inc. | Aptamers specific for thrombin and methods of use |
| US5338671A (en) | 1992-10-07 | 1994-08-16 | Eastman Kodak Company | DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody |
| TW239160B (https=) * | 1992-10-27 | 1995-01-21 | Procter & Gamble | |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US5817635A (en) | 1993-08-09 | 1998-10-06 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
| US5681702A (en) * | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
| US6013443A (en) | 1995-05-03 | 2000-01-11 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
| JP4531132B2 (ja) | 1995-06-02 | 2010-08-25 | ギリード・サイエンシズ・インコーポレーテッド | 増殖因子に対する高親和性オリゴヌクレオチドリガンド |
| US6229002B1 (en) | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
| US6020130A (en) | 1995-06-07 | 2000-02-01 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands that bind to and inhibit DNA polymerases |
| US6111095A (en) * | 1995-06-07 | 2000-08-29 | Merck & Co., Inc. | Capped synthetic RNA, analogs, and aptamers |
| RU2177950C2 (ru) | 1996-10-25 | 2002-01-10 | Нексстар Фармасьютикалз, Инк. | Комплексы нуклеиновых кислот - лигандов сосудистого эндотелиального фактора роста (vegf) |
| US6051698A (en) | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| US7419663B2 (en) * | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
| US6329145B1 (en) * | 1999-02-09 | 2001-12-11 | Gilead Science, Inc. | Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand |
| US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
| EP1383782A1 (en) * | 2001-03-26 | 2004-01-28 | Sirna Therpeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| US20040249130A1 (en) * | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
| US20040022727A1 (en) * | 2002-06-18 | 2004-02-05 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
| US7803931B2 (en) * | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
-
2005
- 2005-02-14 HU HUE14194459A patent/HUE038239T2/hu unknown
- 2005-02-14 SI SI200532210T patent/SI2860251T1/en unknown
- 2005-02-14 EP EP20168481.8A patent/EP3736335A1/en not_active Withdrawn
- 2005-02-14 JP JP2006553313A patent/JP5242918B2/ja not_active Expired - Lifetime
- 2005-02-14 PT PT181569682T patent/PT3385384T/pt unknown
- 2005-02-14 DK DK05713496.7T patent/DK1727567T3/da active
- 2005-02-14 ES ES13150168T patent/ES2531075T3/es not_active Expired - Lifetime
- 2005-02-14 ES ES14194459.5T patent/ES2674129T3/es not_active Expired - Lifetime
- 2005-02-14 DK DK14194459.5T patent/DK2860251T3/en active
- 2005-02-14 ES ES05713496T patent/ES2429442T3/es not_active Expired - Lifetime
- 2005-02-14 DK DK18156968.2T patent/DK3385384T3/da active
- 2005-02-14 HU HUE18156968A patent/HUE050481T2/hu unknown
- 2005-02-14 PL PL14194459T patent/PL2860251T3/pl unknown
- 2005-02-14 EP EP13150168.6A patent/EP2578683B9/en not_active Expired - Lifetime
- 2005-02-14 ES ES18156968T patent/ES2808955T3/es not_active Expired - Lifetime
- 2005-02-14 PT PT141944595T patent/PT2860251T/pt unknown
- 2005-02-14 LT LTEP18156968.2T patent/LT3385384T/lt unknown
- 2005-02-14 WO PCT/US2005/004606 patent/WO2005079363A2/en not_active Ceased
- 2005-02-14 SI SI200532280T patent/SI3385384T1/sl unknown
- 2005-02-14 PT PT57134967T patent/PT1727567E/pt unknown
- 2005-02-14 EP EP05713496.7A patent/EP1727567B1/en not_active Expired - Lifetime
- 2005-02-14 EP EP14194459.5A patent/EP2860251B1/en not_active Expired - Lifetime
- 2005-02-14 LT LTEP14194459.5T patent/LT2860251T/lt unknown
- 2005-02-14 EP EP18156968.2A patent/EP3385384B1/en not_active Expired - Lifetime
- 2005-02-14 PL PL18156968T patent/PL3385384T3/pl unknown
- 2005-02-14 TR TR2018/08488T patent/TR201808488T4/tr unknown
- 2005-12-22 US US11/318,227 patent/US7538211B2/en not_active Expired - Lifetime
-
2006
- 2006-02-14 US US11/354,657 patent/US7579456B2/en not_active Expired - Lifetime
-
2013
- 2013-09-30 CY CY20131100843T patent/CY1114443T1/el unknown
-
2018
- 2018-07-02 CY CY20181100689T patent/CY1120384T1/el unknown
-
2020
- 2020-07-07 CY CY20201100625T patent/CY1123503T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007527714A5 (https=) | ||
| TWI672314B (zh) | 反義核酸 | |
| EP2068935B1 (en) | Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1 | |
| JP2021503940A (ja) | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 | |
| TWI834720B (zh) | 可釋放glp-1共軛物 | |
| US12590304B2 (en) | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | |
| KR20190040098A (ko) | 안티센스 핵산 | |
| EP2455469A1 (en) | Nucleic acid molecule capable of binding to hmgb1, and use thereof | |
| CN1867581B (zh) | Il-21衍生物 | |
| US9492470B2 (en) | Use of HMGA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells | |
| US20200181620A1 (en) | Inhibitors of dek protein and related methods | |
| CN119487192A (zh) | 小激活核酸分子及其在治疗遗传性血管性水肿中的用途 | |
| US9938533B2 (en) | DNA aptamers specific to CD200R1 and their therapeutic uses | |
| CN113365627A (zh) | 用于治疗炎症性肠病的vdac抑制剂 | |
| WO2024208357A1 (zh) | 调控CIDEB mRNA表达的dsRNA分子 | |
| WO2022220216A1 (ja) | アプタマー型マルチウォーヘッド共有結合性薬剤 | |
| WO2017022665A1 (ja) | ｍＲＮＡを効率よく生体内に送達できるポリイオンコンプレックス並びにこれを用いた関節症の治療薬および治療法 | |
| US10584342B2 (en) | DNA aptamers specific to CD2000R1 and their therapeutic uses | |
| JP5777240B2 (ja) | 新規オリゴヌクレオチド誘導体及びそれから成るＮＦ−κＢデコイ | |
| TW202539738A (zh) | 適體及聚乙基噁唑啉之共軛物 | |
| WO2025201467A1 (zh) | 用于抑制中枢神经系统靶基因表达的多肽寡核苷酸缀合物及其应用 | |
| WO2025261376A1 (zh) | 肝外递送配体及其缀合物 | |
| WO2025223229A1 (zh) | 含脂质修饰单体的双链寡核苷酸及其用途 | |
| HK40106707A (zh) | 核酸、药物组合物与缀合物及制备方法和用途 | |
| HK40056335B (zh) | 核酸、药物组合物与缀合物及制备方法和用途 |